TORONTO, May 07, 2025--(BUSINESS WIRE)--Primaris Real Estate Investment Trust ("Primaris" or the "Trust") (TSX: PMZ.UN) announced today that its Board of Trustees has declared a distribution of $0 ...

Good morning and welcome to Primaris REIT’s First Quarter 2025 Results Conference Call. [Operator Instructions] I will now turn the call over to Claire Mahaney, Vice President, Investor ...

Voting results for the individual trustees of the Trust are as follows: In addition, Primaris is pleased to announce that the non-binding advisory resolution on the Trust's approach to executive ...

Occupancy and Leasing Results Primaris’ leasing activities are focused on driving value by actively managing the tenant and merchandising mix at its investment properties. In-place occupancy increased ...

In Minecraft Bedrock Edition, certain hostile mobs can rarely spawn with armor or an item in their hands. Hostile mobs like zombies and skeletons can spawn with iron, gold, or even diamond armor ...

Whatever negative press Bethesda got was seemingly more than offset by the money the Horse Armor DLC raked in. Even lead designer Bruce Nesmith said the team thought its sales were unexpected ...

The Apothecary Diaries season 2 is continuing this spring season with its second part, complete with a new opening and, yes, more episodes – including the upcoming episode 19. Thanks to a ...

Meanwhile, Maomao reaches a remote village with Shisui and their captor, Suirei. As Maomao observes her surroundings with trademark insight, the episode reveals unexpected ties between Suirei and ...

The Ministry of Food and Drug Safety noted on the 24th that it will approve the use of the systemic Myasthenia Gravis treatment, Listigoju (Rozanolixizumab). Myasthenia Gravis is a rare disease ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

The FDA has approved Johnson & Johnson’s nipocalimab (Imaavy) for adults and paediatric patients 12 years of age and older with generalized myasthenia gravis (gMG) and anti-acetylcholine ...